HC Wainwright Lifts Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for TG Therapeutics in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will post earnings of $1.39 per share for the year, up from their prior estimate of $1.26. HC Wainwright currently has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2026 earnings at $2.27 EPS and FY2027 earnings at $2.86 EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million for the quarter, compared to analysts’ expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

Other analysts also recently issued reports about the company. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. Finally, The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Price Performance

NASDAQ:TGTX opened at $35.62 on Wednesday. The firm has a market capitalization of $5.54 billion, a price-to-earnings ratio of -356.16 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The business has a 50 day simple moving average of $30.86 and a 200-day simple moving average of $28.33. TG Therapeutics has a 1 year low of $12.93 and a 1 year high of $36.94.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TGTX. State Street Corp grew its position in shares of TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after buying an additional 2,398,015 shares in the last quarter. Clearbridge Investments LLC bought a new position in TG Therapeutics during the 4th quarter worth about $55,237,000. Principal Financial Group Inc. increased its position in TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the period. Raymond James Financial Inc. bought a new stake in shares of TG Therapeutics in the 4th quarter valued at about $14,508,000. Finally, Braun Stacey Associates Inc. purchased a new stake in shares of TG Therapeutics in the 4th quarter worth approximately $13,328,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.